Contents

Chapter 1 General introduction and scope of the thesis 7

PART I

Chapter 2 Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial
Eur J Cancer. 2014 Dec;50(18):3077-88 17

Chapter 3 Angiogenesis- and hypoxia-associated proteins as early indicators of the outcome in patients with metastatic breast cancer given first-line bevacizumab-based therapy
Clin Cancer Res. 2016 Apr 1;22(7):1611-20 37

Chapter 4 Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: a systematic review
Cancer Treat Rev. 2015 Dec;41(10):935-50 57

Chapter 5 The role of pharmacogenetics in capecitabine efficacy and toxicity
Cancer Treat Rev 2016 (in press) 93

Chapter 6 Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients
Br J Cancer. 2016 (in press) 121

Chapter 7 Genetic polymorphisms in the genes of CES2, CDA and CDA enzymatic activity for prediction of the efficacy of capecitabine-based chemotherapy in patients with metastatic breast cancer
Submitted 139

PART II

Chapter 8 Breast cancer classification by proteomic technologies: current state of knowledge
Cancer Treat Rev. 2014 Feb;40(1):129-38 159

Chapter 9 The cancer secretome, current status and opportunities in the lung, breast and colorectal cancer context
Biochim Biophys Acta. 2013 Nov;1834(11):2242-58 185

Chapter 10 Secretome proteomics reveals non-invasive biomarkers of BRCA1 deficiency in breast cancer
Oncotarget 2016 (in press) 225

Chapter 11 General discussion and future perspectives 245

Appendices

Dutch summary 259
List of publications
Acknowledgements
Curriculum vitae